Ignite Creation Date:
2024-05-06 @ 2:11 PM
Last Modification Date:
2024-10-26 @ 1:26 PM
Study NCT ID:
NCT04240002
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2020-01-21
Brief Title:
A Study of Gilteritinib ASP2215 Combined With Chemotherapy in Children Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 FLT3Internal Tandem Duplication ITD Positive Relapsed or Refractory Acute Myeloid Leukemia AML
Sponsor:
Astellas Pharma Global Development Inc
Organization:
Astellas Pharma Inc
Organization Data
Organization:
Astellas Pharma Inc
Class:
INDUSTRY
Study ID:
2215-CL-0603
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Astellas Pharma Global Development Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None